Faster MRI to watch for ovarian cancer recurrence
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial uses a faster MRI scan to watch for ovarian cancer coming back in women who are at high risk of recurrence while taking PARP inhibitor maintenance therapy. The goal is to find any recurrence early, which may improve the success of a second surgery to remove it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian cancer called high-grade serous, without BRCA mutation and with a normal HR repair (HRP).
- You had no visible tumor left after your first surgery to remove the cancer.
- It has been more than 6 months since your last chemotherapy with a platinum drug.
- You are willing to join the study and give your consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
This trial tests if a second surgery followed by heated chemotherapy delivered directly into the abdomen can help people with ovarian, fallopian tube, or peritoneal cancer whose disease has returned while on a PARP inhibitor.
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.